Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Spektrum der Augenheilkunde 5-6/2015

01.12.2015 | themenschwerpunkt

BCC Update – Diagnostik und Therapie

verfasst von: Ao. Univ.-Prof. Dr. Birgit Lackner, Sara Kazerounian, Roman Dunavölgyi, Andreas Kuchar

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5-6/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Das Basalzellkarzimon (BCC) gehört zu den häufigsten Tumoren in der periorbitalen Region. Aufgrund lokal fortgeschrittener und metastasierender BCC Fälle rückte eine neue Therapieform ins Zentrum klinischer Forschung. Die Entdeckung des Hedgehog Signalwegs führte zu einem neuen Therapieansatz.
Vismodegib, ein Hedgehog Signalweg Inhibitor, wird oral verabreicht und für die Behandlung lokal fortgeschrittener und metastasierender BCC eingesetzt. Bemerkenswerte Tumorrückbildungen sind zu beobachten.
Literatur
2.
Zurück zum Zitat Gilbody JS, Aitken J, Green A. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health. 1994;18(2):218–21. CrossRefPubMed Gilbody JS, Aitken J, Green A. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health. 1994;18(2):218–21. CrossRefPubMed
3.
Zurück zum Zitat Hackethal M, Ulrich C, Stockfleth E. [Skin cancer after organ transplantation]. Dtsch Med Wochenschr. 2006;131(28–29):1609–13. CrossRefPubMed Hackethal M, Ulrich C, Stockfleth E. [Skin cancer after organ transplantation]. Dtsch Med Wochenschr. 2006;131(28–29):1609–13. CrossRefPubMed
4.
Zurück zum Zitat Brash DE, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996;1(2):136–42. PubMed Brash DE, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996;1(2):136–42. PubMed
5.
Zurück zum Zitat Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22(11):853–7. CrossRefPubMed Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22(11):853–7. CrossRefPubMed
6.
Zurück zum Zitat Lang GK. Augenheilkunde. 4 Aufl. Stuttgart: G.T. Verlag; 2008. Lang GK. Augenheilkunde. 4 Aufl. Stuttgart: G.T. Verlag; 2008.
7.
Zurück zum Zitat Ninomiya Y, et al. Photodynamic diagnosis of basal cell carcinoma on the lower eyelid using topical 5-aminolaevulinic acid and desferrioxamine. Br J Dermatol. 1999;141(3):580–1. CrossRefPubMed Ninomiya Y, et al. Photodynamic diagnosis of basal cell carcinoma on the lower eyelid using topical 5-aminolaevulinic acid and desferrioxamine. Br J Dermatol. 1999;141(3):580–1. CrossRefPubMed
8.
Zurück zum Zitat Snow SN, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994;73(2):328–35. CrossRefPubMed Snow SN, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994;73(2):328–35. CrossRefPubMed
9.
Zurück zum Zitat Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 2099–100, 2121. CrossRefPubMed Cook BE Jr, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 2099–100, 2121. CrossRefPubMed
10.
Zurück zum Zitat Schubert J, Muller A. [Basaliomas with invasion of bone: problems and prognosis]. Mund Kiefer Gesichtschir. 1997;1(1):44–6. CrossRefPubMed Schubert J, Muller A. [Basaliomas with invasion of bone: problems and prognosis]. Mund Kiefer Gesichtschir. 1997;1(1):44–6. CrossRefPubMed
11.
Zurück zum Zitat Prabhakaran VC, et al. Basal cell carcinoma of the eyelids. Compr Ophthalmol Update. 2007;8(1):1–14. PubMed Prabhakaran VC, et al. Basal cell carcinoma of the eyelids. Compr Ophthalmol Update. 2007;8(1):1–14. PubMed
12.
Zurück zum Zitat Smeets NW, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol. 2004;151(1):141–7. CrossRefPubMed Smeets NW, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face – results of a retrospective study and review of the literature. Br J Dermatol. 2004;151(1):141–7. CrossRefPubMed
13.
Zurück zum Zitat Howard GR, et al. Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid. Am J Ophthalmol. 1992;113(2):123–33. CrossRefPubMed Howard GR, et al. Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid. Am J Ophthalmol. 1992;113(2):123–33. CrossRefPubMed
14.
Zurück zum Zitat Payne JW, et al. Basal cell carcinoma of the eyelids. A long-term follow-up study. Arch Ophthalmol. 1969;81(4):553–8. CrossRefPubMed Payne JW, et al. Basal cell carcinoma of the eyelids. A long-term follow-up study. Arch Ophthalmol. 1969;81(4):553–8. CrossRefPubMed
15.
Zurück zum Zitat Perlman GS, Hornblass A. Basal cell carcinoma of the eyelids: a review of patients treated by surgical excision. Ophthalmic Surg. 1976;7(4):23–7. PubMed Perlman GS, Hornblass A. Basal cell carcinoma of the eyelids: a review of patients treated by surgical excision. Ophthalmic Surg. 1976;7(4):23–7. PubMed
16.
Zurück zum Zitat Kunte C, Konz B. [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt. 2007;58(5):419–26. CrossRefPubMed Kunte C, Konz B. [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt. 2007;58(5):419–26. CrossRefPubMed
17.
Zurück zum Zitat Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(Suppl 2):S127–47. CrossRefPubMed Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(Suppl 2):S127–47. CrossRefPubMed
18.
Zurück zum Zitat Johnson TM, et al. Unusual basal cell carcinomas. Cutis. 1994;54(2):85–92. PubMed Johnson TM, et al. Unusual basal cell carcinomas. Cutis. 1994;54(2):85–92. PubMed
19.
Zurück zum Zitat Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50. CrossRefPubMed Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50. CrossRefPubMed
20.
Zurück zum Zitat Donovan J. Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009;35(9):1311–23. CrossRefPubMed Donovan J. Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009;35(9):1311–23. CrossRefPubMed
21.
Zurück zum Zitat Springate JE. The nevoid basal cell carcinoma syndrome. J Pediatr Surg. 1986;21(10):908–10. CrossRefPubMed Springate JE. The nevoid basal cell carcinoma syndrome. J Pediatr Surg. 1986;21(10):908–10. CrossRefPubMed
22.
Zurück zum Zitat Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg. 1991;5(6):643–6. CrossRefPubMed Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. Br J Neurosurg. 1991;5(6):643–6. CrossRefPubMed
23.
24.
Zurück zum Zitat Thissen MR, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759–64. CrossRefPubMed Thissen MR, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759–64. CrossRefPubMed
25.
Zurück zum Zitat Olschewski T, et al. [Radiotherapy of basal cell carcinoma of the face and head: importance of low dose per fraction on long-term outcome]. J Dtsch Dermatol Ges. 2006;4(2):124–30. CrossRefPubMed Olschewski T, et al. [Radiotherapy of basal cell carcinoma of the face and head: importance of low dose per fraction on long-term outcome]. J Dtsch Dermatol Ges. 2006;4(2):124–30. CrossRefPubMed
26.
Zurück zum Zitat Mosterd K, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149–56. CrossRefPubMed Mosterd K, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149–56. CrossRefPubMed
27.
Zurück zum Zitat Zagrodnik B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer. 2003;98(12):2708–14. CrossRefPubMed Zagrodnik B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer. 2003;98(12):2708–14. CrossRefPubMed
28.
Zurück zum Zitat Adams EL, Price NM. Treatment of basal-cell carcinomas with a carbon-dioxide laser. J Dermatol Surg Oncol. 1979;5(10):803–6. CrossRefPubMed Adams EL, Price NM. Treatment of basal-cell carcinomas with a carbon-dioxide laser. J Dermatol Surg Oncol. 1979;5(10):803–6. CrossRefPubMed
29.
Zurück zum Zitat Steinmann A, Fukushima M, et al. Gesundheitswesen. 2004;66(Suppl 1):S37–S42. Steinmann A, Fukushima M, et al. Gesundheitswesen. 2004;66(Suppl 1):S37–S42.
Metadaten
Titel
BCC Update – Diagnostik und Therapie
verfasst von
Ao. Univ.-Prof. Dr. Birgit Lackner
Sara Kazerounian
Roman Dunavölgyi
Andreas Kuchar
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 5-6/2015
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-015-0282-5